Member Info for themuir01

haha Mikey

ncyt have done a great job... but their tests are going to be obsolete in about 2-3 months

buy buy buy... you#ll regret it if you dont

To shake the shorts.... sell your shares...

https://www.gelifesciences.com/en/gb

Stocksbof52

rapid 5 minute test...using saliva

antibody test...

sell your aa you fool

how are aa today rampy?

it can by 50 %... I don't care...sell your aa's... dont be daft

:-)

After reading Mcnultys research... a while!!

We make a good partnership Mikey :-) have a feeling this relationship might last longer than the last though haha

Stock.sbof52... sell your AA's... this is once in a lifetime kid.... have a look at GE Healthcare... 7000 staff, already ahve the technology made

Have some money waiting for any dips... hoping to be about 150,000.

Yeah good choice...honestly I was screaming for antibody tests... and are the Americans.. people can go back to work = the economy will restart

So just sold DTG, now Asos

I'm all in!

In January this year, Avacta formed a joint venture with Daewoong Pharmaceutical Co Ltd (‘Daewoong’), a
leading Korean pharmaceutical company. The JV company has been named AffyXell Therapeutics (‘AffyXell’):
it has been established to develop the next generation of cell and gene therapies. These are two overlapping
fields of biomedical research. Cell therapy is therapy in which cellular material – usually intact, living cells – is
injected, grafted or implanted into a patient for the treatment of disease. Gene therapy can be defined as the use
of genetic material (usually DNA) to manipulate a patient’s cells for the treatment of disease.
Cell therapy has been around since the 1940s – the most common type now being bone marrow transplantation.
Bone marrow transplantation is the treatment of choice for many kinds of leukaemia and lymphoma and is also
used to treat many inherited disorders. Gene therapy was introduced in the late 1970s – although the first therapy
was only approved by the US FDA in 2017 (there are now approximately 20 that have been granted marketing
approval).
Mesenchymal stem cells (‘MSC’) are promising agents for the treatment of autoimmune and inflammatory
diseases. They enable “allogeneic cell therapy”, which is when the donor is a different person to the recipient of
the cells. AffyXell’s first area of focus is in cell therapy – specifically in developing a new class of MSCs that are
primed to produce Affimer proteins.
Avacta and AffyXell have already entered into a collaboration and licensing agreement: Avacta will develop
Affimer proteins against a range of targets which, when produced by MSCs, are intended to inhibit inflammatory
and autoimmune pathways and improve the overall efficacy of MSCs.
Daewoong’s role will be to provide AffyXell with access to its proprietary technology for generating the MSCs
themselves. This technology facilitates the development of cell therapies as ‘off-the-shelf’ products, as it enables
the generation of MSCs

In December 2018, the Company formed a major, multi-target, Affimer therapeutics development alliance with
LG Chem Life Sciences (‘LG Chem’), a business division of South Korean multinational conglomerate LG
Group. LG Chem focuses on three key core therapeutic areas, namely: Immunology; Oncology; and Metabolic
Diseases (specifically, diabetes).
As with the Moderna collaboration, much of the detail of this alliance has not been disclosed. Avacta has been
required to generate, and carry out early stage optimisation of, Affimer drug candidates against multiple
undisclosed targets. The Company has achieved this first phase, having successfully generated a large number of
Affimer proteins that bind to the first drug target nominated by LG Chem. These candidate Affimer molecules
are now being optimised by Avacta, for LG Chem to then carry out pre-clinical development.
In November 2019, following Avacta’s successful work on the first nominated drug target, LG Chem expanded
the collaboration by nominating two further drug targets. Avacta is presently carrying out the discovery
programmes for Affimer binders to those new targets.
For each of these three nominated drug targets, LG Chem and Avacta will collaborate to progress them through
to drug candidate selection. Thereafter, LG Chem will be responsible for p

In May 2015, Avacta entered into a collaboration, licensing and option agreement with Moderna Therapeutics.
Moderna is the world leader in drug discovery and drug development based on mRNA. The company creates
synthetic mRNA that can be injected into patients to help them create their own therapies. Moderna has raised
circa $3bn in equity financing since its inception only a decade ago, including $604m upon its NASDAQ IPO at
the end of 2018, and a further $500m last month. Its current market capitalisation is $9.6bn.
The agreement provided Moderna with exclusive access to Affimers against certain targets, and the option to
enter into exclusive license agreements with Avacta for selected therapeutic Affimer candidates for clinical
development. Moderna made an upfront payment of $0.5m and would be obliged to pay up to “several tens of
millions of dollars” in various milestone payments for each Affimer candidate that it licensed.
In February 2019, Moderna exercised its option to enter into an exclusive licensing agreement with respect to
certain Affimers against a single potential therapeutic target that had been part of the ongoing research
17
collaboration since 2015. No details have been given on the specific target, or on the potential financial
implications for Avacta other than that the Company “may receive undisclosed payments upon future clinical development
milestones and royalties in connection with future product sales.”

I watch the Americans every night fro about 3 hours... they are screaming for these type of tests... seems we've struck gold... once in a lifetime?

Amazing research.. Just weighing up... sell DTG, NEX and Asos... or them all.. maybe them all

Looks like your long waits going to be paid off Roy